Home » Stocks » BSTC

Biospecifics Technologies Corp. (BSTC)

Dec 3, 2020 - BSTC was delisted (reason: acquired by Endo International)
Stock Price: $88.53 USD 0.00 (0.00%)
Updated Dec 1, 2021 4:00 PM EST
Market Cap 650.25M
Revenue (ttm) 36.59M
Net Income (ttm) 17.36M
Shares Out 7.34M
EPS (ttm) 2.36
PE Ratio 37.51
Forward PE 17.61
Dividend n/a
Dividend Yield n/a
Trading Day Dec 1, 2021
Last Price $88.53
Previous Close $88.53
Change ($) 0.00
Change (%) 0.00%
Day's Open 88.47
Day's Range 88.44 - 88.57
Day's Volume 88,956
52-Week Range 0.00 - 88.57

News

Hide News
PRNewsWire - 2 months ago

NEW YORK, Oct. 27, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection wi...

Business Wire - 3 months ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioSpeci...

PRNewsWire - 3 months ago

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 21, 2020) - [DATELINE]Rowley Law PLLC is investigating potential securities law violations by BioSpecifics Technologies Corp. (NASDAQ: BSTC) and i...

Other stocks mentioned: ENDP
The Motley Fool - 3 months ago

Investors are fired up about Endo's planned acquisition of BioSpecifics.

Other stocks mentioned: ENDP
Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 19, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased BioSpecifics Technologies C...

24/7 Wall Street - 3 months ago

News that Endo International PLC (NASDAQ: ENDP) would acquire BioSpecifics Technologies Corp.

Other stocks mentioned: ENDP
Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of BioSpecifics Technologies Corp. (NASDAQ: BSTC) to Endo International plc fo...

PRNewsWire - 3 months ago

WILMINGTON, Del., Oct. 19, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced today that it has entered into a definitive merger agreement under which Endo Internati...

Other stocks mentioned: ENDP
PRNewsWire - 3 months ago

-- Endo to acquire BioSpecifics in an accretive all-cash transaction -- DUBLIN, Oct. 19, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced it has agreed to acquire all...

Other stocks mentioned: ENDP
PRNewsWire - 4 months ago

WILMINGTON, Del., Sept. 14, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp.

PRNewsWire - 4 months ago

WILMINGTON, Del., Sept. 8, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp.

Zacks Investment Research - 5 months ago

BioSpecifics (BSTC) delivered earnings and revenue surprises of 320.00% and 89.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 months ago

Shares of BioSpecifics Technologies (NASDAQ:BSTC) rose 2% in pre-market trading after the company reported Q2 results.

Zacks Investment Research - 5 months ago

BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 6 months ago

WILMINGTON, Del., July 20, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp.

Seeking Alpha - 7 months ago

BioSpecifics Technologies Could Surge If The FDA Approves Its 'CCH' In XiaFlex To Treat Cellulite In The Buttocks

Zacks Investment Research - 8 months ago

Cash is the lifeblood of any business, and provides vitality and strength to a company.

Other stocks mentioned: ESLT, EXPI, VOPKY
Zacks Investment Research - 8 months ago

Is (BSTC) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 9 months ago

Cash provides vitality and strength to a company. It holds the key to the company's existence, development and success, and can indeed be referred to as its lifeblood.

Other stocks mentioned: CBZ, EXPI, PJT, ROCK
Zacks Investment Research - 9 months ago

Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.

Other stocks mentioned: CBZ, CHRS, DHT, EURN, ITGR, ROCK
Zacks Investment Research - 9 months ago

Is (BSTC) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 9 months ago

BioSpecifics (BSTC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GuruFocus - 9 months ago

As of March 30, the following companies could be undervalued by the market, as their price-earnings ratios are below 20 and their price-earnings to growth (aka PEG) ratios stand below 1.

Other stocks mentioned: JBT, PAGS
Zacks Investment Research - 1 year ago

BioSpecifics (BSTC) delivered earnings and revenue surprises of 13.33% and 6.57%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

BioSpecifics (BSTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 1 year ago

Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.

Other stocks mentioned: ENDP, FGEN, VXRT
Zacks Investment Research - 1 year ago

In the long-run, does consistent market timing really matter to be a successful investor?

Other stocks mentioned: CMD, CSBR, RDNT, TRXC
Seeking Alpha - 1 year ago

Biospecifics has recurring royalty revenue expected to grow 10%-15% annually from two Xiaflex indications.

Zacks Investment Research - 1 year ago

BioSpecifics Technologies (BSTC) will provide updates on Xiaflex and pipeline progress, when it releases first-quarter 2019 results.

Zacks Investment Research - 1 year ago

BioSpecifics (BSTC) is well positioned to outperform the market, as it exhibits above-average growth in financials.

About BSTC

BioSpecifics Technologies, a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement wi... [Read more...]

Industry
Biotechnology
IPO Date
Nov 14, 1991
Stock Exchange
NASDAQ
Ticker Symbol
BSTC
Full Company Profile

Financial Performance

In 2019, BSTC's revenue was $38.19 million, an increase of 15.86% compared to the previous year's $32.96 million. Earnings were $24.47 million, an increase of 22.02%.

Financial Statements